ERBB2 and colorectal carcinoma: Notably, HER2 CAR-T cells displayed greater aggressiveness in the HER2+ CRC in patient-derived tumor xenograft (PDX) models and demonstrated potent immunotherapeutic capacity for mCRC in the metastatic xenograft mouse models.